- InflaRx N.V. (NASDAQ:IFRX) provided a development update for its monoclonal anti-C5a antibody, vilobelimab, in pyoderma gangrenosum (PG) and severe COVID-19.
- The FDA and the European Medicines Agency (EMA) have granted orphan drug designation to vilobelimab for PG.
- PG is a rare condition that causes large, painful sores (ulcers) to develop on the skin.
- In addition, the company had a productive FDA end-of-phase II meeting to its plans for a Phase 3 development program in PG.
- The FDA indicated its support for a randomized, controlled Phase 3 study and offered to review the study protocol.
- Based on the agency's feedback and recommendations, InflaRx is now finalizing the design for a Phase 3 trial.
- InflaRx requested a meeting with the FDA to obtain guidance for a potential emergency use authorization submission of vilobelimab in COVID-19 patients.
- Related: InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients.
- This has been scheduled as a Type B meeting for early Q3. In addition, the company is in ongoing dialogue with the EMA about the next steps in developing vilobelimab in mechanically ventilated severe COVID-19 patients.
- Price Action: IFRX shares were down 6.91% at $1.42 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
InflaRx Provides Development Update For Vilobelimab In Skin Disorder, COVID-19
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks